A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma

Cancer Investigation

Volumn 31, Issue 3, 2013, Pages 172-176

  Held, Lauren A ^a   Rizzieri, David ^a   Long, Gwynn D ^a   Gockerman, Jon P ^a   Diehl, Louis F ^a   Castro, Carlos M De ^a   Moore, Joseph O ^a   Horwitz, Mitchell E ^a   Chao, Nelson J ^a   Gasparetto, Cristina ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Clinical trials; Myeloma

Indexed keywords

ARSENIC TRIOXIDE; ASCORBIC ACID; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; MELPHALAN; PREDNISONE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EXPOSURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOTENSION; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; ASCORBIC ACID; BORONIC ACIDS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OXIDES; PYRAZINES; RECURRENCE;

EID: 84875033710     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2012.756109     Document Type: Article

References (23)

1. Barlogie B, Epstein J, Selvanayagam P, Alexinian R. Plasma cell myeloma: new biological insights and advances in therapy. Blood 1989;73:865-879.
2. Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BG, Taylor CW, Miller TP, Salmon SE. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Oncol 1989;7:415-424.
3. Group MTsC. Combination chemotherapy vs. melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 1998;16:3832-3842.
4. Adams J, Palombella VJ, Elliot PJ. Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs 2000;18:109-121.
5. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-2622.
6. Richardson P. Clinical update: proteasome inhibitors in hematologic malignancies. Cancer Treat Rev 2003;29(Suppl. 1):33-39.
7. Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, Neil J, Reis I, Kharfan-Dabaja M, Eckman J, Goodman M, Fernandez HF, Boise LH, Lee KP. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res 2002;8:3658-3668.
8. LiuQ, Hilsenbeck S, Gazitt Y. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase 8 or caspase 9 and synergy with APO2/TRAIL. Blood 2003;10:4078-4087.
9. Wu X, Shi J, Wu Y, Tao Y,Hou J, Meng X, Hu X, Han Y, JiangW, Tang S, Zangari M, Tricot G, Zhan F. Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2. Cancer BiolTher 2010;10:1201-1214.
10. Miller WH, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002;62:3893-3903.
11. Huang CH, Chen WJ, Wu CC, Chen YC, Lee YT. Complete atrioventricular block after arsenic trioxide treatment in an acute promyelocytic leukemic patient. Pacing Clin Electrophysiol 1999;22:965-967.
12. Sanaat Z, Rezazadeh M, Gharamaleki JV, Ziae JE, Esfahani A. Arsenic trioxide in patients with refractory multiple myeloma: a prospective, phase II, single-arm study. Acta Med Iran 2011;49:504-508.
13. Hussein MA, Saleh M, Ravandi F, Mason J, Rifkin RM, Ellison R. Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma. Br J Haematol 2004;125:470-476.
14. Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, Neil J, Reis I, Kharfan-Dabaja M, Eckman J, Goodman M, Fernandez H, Boise LH, Lee KP. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res 2002;8:3658-3668.
15. Campbell RA, Sanchez E, Steinberg JA, Baritaki S, Gordon M, Wang C, Shalitin D, Chen H, Pang S, Bonavida B, Said J, Berenson Jr. Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid. Br J Haematol 2007;138:467-478.
16. Ge QF, Ouyang GF, Chen Y, Zhang Y, Mu QT, Lu Y. Effects of arsenic trioxide combined with bortezomib on apoptosis of multiple myeloma cell line KM3 and its mechanisms. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2012;20:112-115.
17. Jung HJ, Chen Z, McCarty N. Synergistic anticancer effects of arsenic trioxide with bortezomib in mantle cell lymphoma. Am J Hematol 2012; doi: 10.1002/ajh.23317.
18. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999;5:2638-2645.
19. Durie BGM, Harousseau J-L, Miguel JS, Blad'e J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley14 J, Belch A, Boccadaro M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV. On behalf of the International Myeloma Working Group2. International uniform response criteria for multiple myeloma. Leukemia 2006;20: 1467-1473.
20. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG; Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-917.
21. Wang Y, Ai L, Cui G, Gowrea B, Li M, Hu Y. Once- versus twice-weekly Bortezomib induction therapy with dexamethasone in newly diagnosedmultiplemyeloma. JHuazhongUniv Sci Technolog Med Sci 2012;32:495-500.
22. National Comprehensive Cancer Network ® (NCCN). Practice Guidelines in Oncology: Acute Myeloid Leukemia, Version 3, 2010. www.nccn.or.
23. Berenson J, Matous J, Swift R, Mapes R, Morrison B, Yeh HS. A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res 2007;13: 1762-1768.